These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Current status of maintenance therapy in peptic ulcer disease. The ACG Committee on FDA-Related Matters. Am J Gastroenterol; 1988 Jun; 83(6):607-17. PubMed ID: 2897783 [No Abstract] [Full Text] [Related]
44. [Emergency surgery of complicated gastroduodenal ulcers: risk factors and results]. Huber O; Houriet M; Kobel T; Rohner A Schweiz Med Wochenschr; 1985 Jul; 115(29):1019-21. PubMed ID: 4048900 [TBL] [Abstract][Full Text] [Related]
46. Helicobacter pylori infection and the use of NSAIDs. Bazzoli F; De Luca L; Graham DY Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):775-85. PubMed ID: 11566040 [TBL] [Abstract][Full Text] [Related]
47. Evaluation of a new bismuth-free triple therapy in nude mice and humans. Karita M; Tsuda M; Okita K; Sugiyama T; Nakazawa T Eur J Gastroenterol Hepatol; 1995 Aug; 7 Suppl 1():S31-4. PubMed ID: 8574732 [TBL] [Abstract][Full Text] [Related]
48. [Application of the "protection test" in studying blood serum in gastroduodenal ulcers]. BENDA R; CARVAILLO R; MIRAVET LF; GARTENLAUB G Schweiz Z Pathol Bakteriol; 1958; 21(2):338-44. PubMed ID: 13555795 [No Abstract] [Full Text] [Related]
49. [Problems in the traditional pharmacotherapy and prevention of peptic ulcer]. Ryss ES Ter Arkh; 1984; 56(9):106-10. PubMed ID: 6393409 [TBL] [Abstract][Full Text] [Related]
50. Audit of the change of outcome of peptic ulcer disease following treatment of Helicobacter pylori. Jost C; Marbet UA Schweiz Med Wochenschr; 1998 Jan; 128(3):64-71. PubMed ID: 9498257 [TBL] [Abstract][Full Text] [Related]
51. [Pharmacoeconomics in the therapy of peptic ulcer]. Tesar T; Foltán V; Huorka M Ceska Slov Farm; 2002 Mar; 51(2):78-83. PubMed ID: 11928281 [TBL] [Abstract][Full Text] [Related]
52. Tricyclic antidepressants. Drugs for other diseases. Richelson E Arch Intern Med; 1982 Feb; 142(2):231-2. PubMed ID: 6120684 [No Abstract] [Full Text] [Related]
53. Maintenance treatment with H2 receptor antagonists in patients with peptic ulcer disease: reduces morbidity in a significant minority of patients. Wormsley KG BMJ; 1988 Nov; 297(6660):1392, 1394. PubMed ID: 2905897 [No Abstract] [Full Text] [Related]
54. Role of protective drugs in the prevention of ulcer relapse. Ota S; Terano A J Gastroenterol; 1994 Jul; 29 Suppl 7():139-40. PubMed ID: 7921147 [TBL] [Abstract][Full Text] [Related]
55. [Prevention of recurrence of peptic ulcers]. Fölsch UR Verh Dtsch Ges Inn Med; 1989; 95():319-22. PubMed ID: 2574921 [No Abstract] [Full Text] [Related]
56. [Experimental study of Dolispan in the therapy of peptic ulcer]. Manolov P; Todorov S Eksp Med Morfol; 1974; 13(1):36-9. PubMed ID: 4151718 [No Abstract] [Full Text] [Related]
57. The medical therapy of peptic ulcer. Bevan G Postgrad Med J; 1975; 51(5 Suppl):14-8. PubMed ID: 7780 [No Abstract] [Full Text] [Related]